Tune Therapeutics isn’t the only Triangle biotech startup to have recently raised north of $100 million. In August, the Research Triangle Park-based company Pathalys Pharma secured $105 ...

Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years.

Tune Therapeutics isn’t the only Triangle biotech startup to have recently raised north of $100 million. In August, the Research Triangle Park-based company Pathalys Pharma secured $105 ...

A new CEO is leading a Durham biotechnology company that recently closed a $175 million funding round.

This year, Tune Therapeutics Principal Scientist Brian Cosgrove shared new in vitro and in vivo data, showcasing Tune’s clinically optimized liver-targeting LNP-RNA epi-silencing drug (Tune-401 ...

DURHAM, N.C. & SEATTLE, January 13, 2025--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates ...

Tune Therapeutics, a Durham biotechnology startup co-founded by a Duke professor, announced the completion of its Series B fundraising round on Jan. 12, in which it raised $175 million to support ...

DURHAM, N.C. & SEATTLE, January 07, 2025--Leading epigenetic therapy company Tune Therapeutics announced today that it will begin a clinical trial in Hong Kong after receiving a Certificate for ...

Tune Therapeutics is pioneering a new therapeutic modality (termed epigenome editing or genetic tuning) that enables the targeted control of gene expression without cutting or resequencing DNA.

We actually know which genes to tune for that. And the ability to set their volume gauges to zero, to 10,000, or anywhere in between is ultimately where the next generation of therapeutics are headed.

Spyre Therapeutics, Inc. has promising assets in early-stage development, including SPY001, SPY002, and SPY003. Learn more about SYRE stock here.